Dear Editors, In a recent paper in JIMD Reports, Al Khallaf et al present two siblings (ages 4.5 and 2 years, respectively) with infantile Pompe disease (IPD). Despite being CRIM-negative [as determined by CRIM analysis using monoclonal antibodies specific for acid a-glucosidase (GAA)] and treated chronically with Myozyme® (alglucosidase alfa; rhGAA) enzyme replacement therapy (ERT), these patients had "unusually low anti-rhGAA antibody titers and good clinical outcome." As the authors mention, the favorable outcomes seen in these children could potentially be due to the fact that they are, in fact, CRIM-positive as one of their mutations is a splice mutation. Though not detected by western blot, it is conceivable that sufficient enzyme protein is, nonetheless, detected by the immune system, which tolerizes to a significant extent. In addition, the authors speculate that the lower antibody titers seen in patient 2 could be due to her very early ERT initiation (at age 6 days) compared to her older brother (patient 1), who had commenced ERT at several months of age.
Early initiation of ERT (defined here as ≤ 31 days) is important because of rapid disease progression in IPD. However, early commencement of ERT does not necessarily explain low(er) or no antibody formation, or necessarily preclude the possible need for immune tolerance induction (ITI), ceteris paribus. In two previous studies (Kishnani et al 2010; Banugaria et al 2011) , some CRIM-negative and CRIM-positive patients developed high and sustained antibody titers despite early (age ≤ 31 days) initiation of ERT. This observation is further supported by data shown in Fig. 1 (Genzyme Corp.) for the 28 patients identified as ≤ 31 days old at the start of Myozyme® treatment (range: 1 to 31 days; mean: 17 days; median: 21 days). Two of 28 patients were CRIM-negative; information regarding CRIM status for the remaining patients was unavailable. In this cohort of 28 patients, 24 patients (86 %) had seroconverted. The median peak titer for these 24 patients was 6400. Five of 24 patients (21 %; including the two known CRIM-negative patients) had peak titers ≥ 25,600 sustained for periods of time ranging from 3 months to > 1 year. One of the two documented CRIM-negative patients is also described in Abbott et al (2011) . This patient commenced ERT at day 10 of life [her parents had declined immune tolerance induction (ITI)] and had a peak titer of 25,600 at month 27 of ERT. The second CRIM-negative patient commenced ERT at age 2 weeks and had a peak titer of 409,600. Two of the 28 patients received immunomodulation (CRIM status unknown): one patient had a peak titer of 51,600, which persisted for 6 months post-peak before declining to 200 subsequent to immunomodulation; the second patient received ITI prophylactically and as of the last study time point had not seroconverted. Neutralizing antibody activity, including neutralization of enzyme uptake and catalytic activity, was tested in six of 28 patients. The single patient who tested positively (for inhibition of enzyme uptake) had a high sustained antibody titer of 409,600. While "early ERT initiation" in this analysis was considered as ERT commenced at or before 31 days of age, data from future studies [including those related to newborn screening (NBS)] could lead to a reconceptualization of what is conceived of as "early ERT initiation" and the timescale generally applied.
In a case report by Rohrbach et al (2010) , the authors concluded that an IgE inhibitor, omalizumab, used to mitigate the allergic response, could have played an immunomodulatory role that limited the formation of anti-Myozyme® IgG antibodies in this patient. Based on findings from the subsequent study by Abbott et al involving a CRIM-negative patient who had only moderately increased, yet persistent, titers ("atypical immune response"), as well as the two new cases from Al Khallaf et al (none of the three patients represented in these two studies received ITI), it is evident that some patients designated as CRIM-negative do not develop high antibody titers with ERT. As we have previously discussed in Abbott et al (2011) , the persistence of titers (not just the presence of high titers per se) could potentially have important clinical implications. In the case by Abbott et al, the patient's titers peaked at 25,600 after approximately two years of treatment. Titers then fluctuated between 12,800 and 25,600 over the subsequent six months. Although titers ultimately decreased to 6400 the following year (without immunomodulation, and similar to titers seen for patient 1 in Al Khallaf et al), her demise was associated with titers sustained in this 6400 range. This contrasts with what has been seen in long-term infantile survivors, who at most recent follow-up (n=10; time on ERT 23-129 months), had titers of 0 to 1600 (Prater et al 2012) . The potential clinical impact of titers that persist in low to moderate ranges has yet to be fully characterized and warrants further study.
At present, there is limited information to accurately predict which patients with CRIM-negative IPD are unlikely to develop HSAT or very low titers with regular ERT administration (ERT initiated without ITI). Indeed, most CRIMnegative patients treated in this manner have developed HSAT and have had poor clinical outcomes (e.g., Banugaria et al 2011) . The risk-benefit ratio, therefore, supports the administration of prophylactic short-term ITI (relatively more safe) to CRIM-negative patients at the time of ERT initiation, as opposed to longer-term immune suppression (relatively less safe and less certain efficacy) once HSAT has developed (Messinger et al 2012; Banugaria et al 2013) .
The report by Al Khallaf et al builds upon our knowledge that amongst patients designated as CRIM-negative who receive ERT (without ITI), there appears to be a small subset that does not develop high titers per se, but rather a more variable antibody response. However, it is important to remember that the vast majority of CRIM-negative patients (even those diagnosed early, e.g., age ≤ 31 days) do develop high and sustained titers. Consequently, at this time, the riskbenefit ratio justifies the use of ITI in all CRIM-negative patients at the start of ERT. We are continuing to assess the potential clinical impact of antibody titers (low to moderate titers) that remain sustained. Further work exploring the basis for variable immune responsiveness in such patients, including age at start of ERT, potential HLA associations, whether the CRIM assay may miss some CRIM-positive patients, and other genomic factors, is needed. Amy S. Rosenberg reports no competing interests. Priya S. Kishnani reports receiving research and grant support from Genzyme. She also receives honoraria and consulting fees from Genzyme and is a member of the Pompe disease and the Gaucher Disease Registry Advisory Boards.
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